NCT02836548View on ClinicalTrials.gov

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
MelanomaSkin Neoplasms
Interventions
DRUG

Vorinostat

vorinostat 360 milligram once daily

Trial Locations (1)

1066 CX

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam

All Listed Sponsors
lead

The Netherlands Cancer Institute

OTHER

NCT02836548 - HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma | Biotech Hunter | Biotech Hunter